Asset profile

Almonertinib

Small molecule

Phase 3underway

Evidence outlook · registrational

Non-Small Cell Lung Cancer: registrational readout pending

Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2026-09-01.

How the evidence outlook works ↗

Upcoming events

(9 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (2)
September 2026 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-09-01 · NCT06043973 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (1)
Phase 3Lung CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT04841811 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (5)
January 2027 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-01-16 · NCT06752408 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2027 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-05-05 · NCT06951464 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2027 (1)
Phase 1/2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-07-30 · NCT05503888 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (2)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12 · NCT05800223 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-12 · NCT06452433 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (1)
December 2028 (1)
Phase 3Brain Metastases, Radiotherapy, EGFR Activating MutationRecruiting
Est. primary completion 2028-12-31 · NCT05768490 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2032 (1)
November 2032 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2032-11 · NCT07183189 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.